Boston Scientific raises share repurchase authorization to $5B

In a regulatory filing, the company said, “On February 18, 2026, the Board approved an increase to the company’s existing authorization to repurchase up to $1.0 billion of the company’s common stock by an additional $4.0 billion. As a result, the company is authorized to repurchase up to a total of $5.0 billion of common stock under the company’s stock repurchase program, all of which remains available as of the date hereof.”